Intellia Therapeutics (NTLA) Surges 13.10% on ARK ETFs' $2.47M Stake in Gene-Editing Pioneer

The share price rose to its highest level so far this month, with an intraday gain of 7.52%.

Intellia Therapeutics Inc. (NASDAQ: NTLA) saw renewed institutional interest after Cathie Wood’s ARK ETFs, including ARKK and ARKG, executed a $2.47 million purchase of 216,411 shares on Jan. 13. The move, part of a broader strategy to accumulate stakes in biotechnology and genomics, highlights growing confidence in Intellia’s CRISPR-based therapeutic pipeline.

The stock’s 13.10% surge over two days reflects market optimism about the company’s role in advancing gene-editing treatments for genetic disorders.

ARK’s thematic focus on innovation and its historical support for biotech firms position the fund as a bellwether for sector trends. By building a long-term position in Intellia, ARK signals a belief in the company’s ability to capitalize on the expanding gene-editing market. This institutional backing could amplify investor sentiment, potentially stabilizing the stock amid broader biotech sector volatility. The timing of the investment, just ahead of the stock’s record intraday gain, underscores its immediate impact on market dynamics.